GLSI - Greenwich Lifesciences Inc

GLSI - Greenwich Lifesciences Inc

https://greenwichlifesciences.com

Strong Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

GlobeNewswire • 5 days, 5 hours ago • score: 0.04

STAFFORD, Texas, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

GlobeNewswire • 3 weeks, 5 days ago

STAFFORD, Texas, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

GlobeNewswire • 3 weeks, 6 days ago • score: 0.01

STAFFORD, Texas, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

GlobeNewswire • 1 month ago • score: -0.04

STAFFORD, Texas, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

GlobeNewswire • 1 month ago • score: -0.05

STAFFORD, Texas, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously ...

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

GlobeNewswire • 5 months, 1 week ago • score: 0.08

STAFFORD, Texas, April 02, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

GlobeNewswire • 5 months, 2 weeks ago • score: 0.00

STAFFORD, Texas, March 27, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

GlobeNewswire • 5 months, 4 weeks ago • score: 0.11

STAFFORD, Texas, March 17, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

GlobeNewswire • 7 months ago • score: 0.05

STAFFORD, Texas, Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

GlobeNewswire • 7 months, 2 weeks ago • score: -0.03

STAFFORD, Texas, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Greenwich LifeSciences, Inc. ( Nasdaq: GLSI ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.

52W High

$16.50

52W Low

$8.06

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

3.16

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-21.23

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

103.49

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

51.30%

Institutions (25–75% balanced)

10.45%

Shares Outstanding

13,630,300

Float

6,374,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.37

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-4.92%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.1106

Previous

-0.1063

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025